External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology

Haematology

Haematology is a complex and challenging area of medicine that encompasses different diseases ranging from cancers of the blood to bleeding disorders such as haemophilia. Though diverse in nature, what is often common across many of these diseases is the serious impact they can have on either a patient’s survival or quality of life. Blood cancers represent the fifth most common cause of cancer-related death worldwide, with the three most common types being lymphoma, leukaemia and myeloma.

Learn more about the latest advances in Roche haematology research.

Disease
Hemophilia A Leukemia & Lymphoma Materials Chronic Lymphocytic Leukemia Polycythemia Vera Multiple Myeloma Non-Hodgkin Lymphoma Follicular Lymphoma Acute Myeloid Leukemia Paroxysmal Nocturnal Hemoglobinuria Atypical Haemolytic Uraemic Syndrome Sickle Cell Anemia Blood Coagulation Disorder Relapsed refractory multiple myeloma

Preview the latest medical materials

  • Haematology

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Eculizumab
At the primary analysis, the global, randomized, Phase III COMMODORE 1 study showed that crovalimab▼ was well tolerated and had similar exploratory efficacy in patients with paroxysmal nocturnal hemoglobinuria who switched from eculizumab to crovalimab▼ compared with those who continued receiving eculizumab. This poster reports long-term efficacy and safety data from COMMODORE 1, with a median follow-up duration of 2 years.
Haematology Paroxysmal Nocturnal Hemoglobinuria AAMDSIF-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
At the primary analysis, the global, randomized, Phase III COMMODORE 2 study demonstrated the non-inferior efficacy of crovalimab▼ vs eculizumab for co-primary efficacy endpoints of hemolysis control and transfusion avoidance in patients naive to complement inhibition, with a comparable safety profile. This poster reports long-term efficacy and safety data from COMMODORE 2, with a median follow-up duration of 2 years.
Haematology Paroxysmal Nocturnal Hemoglobinuria AAMDSIF-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab▼ (Crova) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab (Ravu)
The global, randomized Phase III COMMODORE 1 study showed similar safety and exploratory efficacy for crovalimab▼ vs eculizumab in randomized patients who received prior eculizumab treatment; this study also enrolled non-randomized patients who switched from ravulizumab to crovalimab▼. This poster reports efficacy and safety data from the COMMODORE 1 ravulizumab switch cohort, with a median treatment duration of approximately 2 years.
Haematology Paroxysmal Nocturnal Hemoglobinuria AAMDSIF-2025
View full list of congress materials
Upcoming congresses
Access to Roche and Genentech's latest medical information

Sign up or login to unlock the full suite of MEDICALLY features
May 15 - May 18, 2025 / Paris, France / Virtual (Hybrid)
COMy 2025
Haematology
Subject:
The 11th World Congress on Controversies in Multiple Myeloma
Venue:
Medical Booth Number:
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Sign up or login to unlock the full suite of MEDICALLY features
May 15 - May 16, 2025 / Paris, France
IPIG 2025
Haematology
Subject:
International PNH Interest Group - 2nd International Conference
Venue:
Medical Booth Number:
Notify me

Sign up or login to unlock the full suite of MEDICALLY features
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.